Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Zymeworks Announces Additional Leadership Appointments
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
Zymeworks Added to Nasdaq Biotechnology Index
Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral […]
Zymeworks Announces Participation in Upcoming Investor Conference
